WuXi AppTec Co., Ltd. logo

WuXi AppTec Co., Ltd. (2359)

Market Closed
24 Jun, 08:00
HKEX HKEX
141. 70
HKD
+10.9
+8.3333%
HKD
- Market Cap
- P/E Ratio
3.96% Div Yield
12.47M Volume
- Eps
130.8 HKD
Previous Close
Add Transaction
Day Range
131.3 145
Year Range
74.65 148
Want to track 2359 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

2359 closed today higher at 141.7 HKD, an increase of 8.3333% from yesterday's close, completing a monthly increase of 9.845% or 12.7 HKD. Over the past 12 months, 2359 stock gained 43.5664%.
2359 pays dividends to its shareholders, with the most recent payment made on May 22, 2026. The next estimated payment will be in In 4 months on Nov 22, 2026 for a total of 1.8028 HKD.
The last earnings report, released on Apr 27, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
WuXi AppTec Co., Ltd. has completed 3 stock splits, with the recent split occurring on May 28, 2021.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

2359 Chart

WuXi AppTec Co., Ltd. (2359) FAQ

What is the stock price today?

The current price is 141.70 HKD.

On which exchange is it traded?

WuXi AppTec Co., Ltd. is listed on HKEX.

What is its stock symbol?

The ticker symbol is 2359.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.96%.

What is its market cap?

As of today, no market cap data is available.

Has WuXi AppTec Co., Ltd. ever had a stock split?

WuXi AppTec Co., Ltd. had 3 splits and the recent split was on May 28, 2021.

WuXi AppTec Co., Ltd. Profile

Professional Services Industry
Industrials Sector
Ge Li CEO
HKEX Exchange
CNE100003F19 ISIN
CN Country
39,414 Employees
30 Apr 2026 Last Dividend
28 May 2021 Last Split
- IPO Date

Overview

Founded in 2000 and headquartered in Shanghai, WuXi AppTec Co., Ltd. stands as a beacon in the pharmaceutical and biotechnological sectors, primarily serving in the People's Republic of China, the United States, Europe, and other international markets. This investment holding company has etched its name as a leader in providing comprehensive research and manufacturing services tailored to facilitate the discovery, development, and manufacturing of a wide spectrum of small molecule drugs and advanced therapies. Operating through its six distinct segments, namely WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others, WuXi AppTec has established a formidable presence in its domain. Its services span across contract research, development, and manufacturing organization domains, covering new drug development from conceptualization to commercialization across a varied range of synthetic molecular modalities.

Products and Services

  • Contract Research, Development, and Manufacturing Organization Services

    WuXi AppTec offers an extensive portfolio of services encompassing the entire lifecycle of new drug development. This includes discovery, development, and manufacturing services for small molecules, oligonucleotides, peptides, and complex conjugates. The company's approach integrates both the chemical and biological aspects of drug development to cater to the pharmaceutical and biotech industries effectively.

  • Biology Services and Solutions

    The company delivers robust biology services and solutions, supporting projects from target discovery through to candidate selection and clinical trials. These services are designed to be both stand-alone and integrated, offering a comprehensive support system for new drug discovery and development.

  • Drug and Medical Device Testing Services

    WuXi AppTec provides a wide range of testing services encompassing preclinical and clinical trials. This includes extensive pharmacology, toxicology, and safety evaluation research services aimed at ensuring the efficacy and safety of new medical interventions.

  • Integrated End-to-End Solution for Cell and Gene Therapies

    To accelerate the market introduction of cell and gene therapies, the company provides an integrated end-to-end solution. This vertical enables seamless progression from research to commercialization, ensuring that these pioneering treatments reach patients faster.

  • Drug Discovery Services

    Catering specifically to pharmaceutical and biotech clients, WuXi AppTec's drug discovery services are designed to streamline the process of new therapeutic discoveries. By leveraging its expertise and resources, the company positions itself as a critical ally in the drug discovery process.

  • Consulting Services for Combinatorial Chemistry and Pharmaceuticals

    WuXi AppTec extends its expertise into consulting services, focused on combinatorial chemistry and pharmaceuticals. This service is aimed at providing strategic insights and solutions to overcome the complex challenges in drug development.

  • Software Development and Database Services

    Understanding the pivotal role of technology in pharmaceutical research, the company has ventured into developing computer software and databases. These technological tools are crafted to bolster research efficiency and data management for its clients.

Contact Information

Address: 288 Fute Zhong Road
Phone: 86 21 5046 1111